AIT Therapeutics (AITB) and Its Competitors Head to Head Survey

AIT Therapeutics (OTCMKTS: AITB) is one of 106 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its competitors? We will compare AIT Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Valuation & Earnings

This table compares AIT Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AIT Therapeutics N/A -$18.04 million -0.97
AIT Therapeutics Competitors $1.51 billion $109.39 million -201.01

AIT Therapeutics’ competitors have higher revenue and earnings than AIT Therapeutics. AIT Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares AIT Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AIT Therapeutics N/A N/A -377.29%
AIT Therapeutics Competitors -57.34% -61.60% -17.85%

Insider and Institutional Ownership

46.1% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.9% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for AIT Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AIT Therapeutics 0 0 3 0 3.00
AIT Therapeutics Competitors 528 1977 3865 132 2.55

AIT Therapeutics currently has a consensus target price of $16.00, indicating a potential upside of 446.08%. As a group, “Surgical & medical instruments” companies have a potential upside of 3.76%. Given AIT Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe AIT Therapeutics is more favorable than its competitors.

AIT Therapeutics Company Profile

AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company's pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis (RSV), cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections. The company was founded in 2011 and is based in Ness Ziona, Israel.

Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply